利福布汀纸片扩散法在螯合MHA上用于鲍曼不动杆菌药敏试验的方法学框架
针对耐碳青霉烯鲍曼不动杆菌(CRAB),利福布汀(RBT)在常规富铁MH培养基中药敏试验活性被系统性低估。本研究遵循CLSI M23指南,在标准及螯合MHA(含EDTA)上评估不同纸片含量,将抑菌圈直径与琼脂稀释法MIC关联。20-μg RBT纸片在螯合MHA或含100 mg/L EDTA的MHA上可清晰可重复区分暂定野生型与非野生型,并初步支持NCTC 13304为候选质控株。
要点
- 常规富铁MHA会系统性低估利福布汀对鲍曼不动杆菌的活性。
- 20-μg利福布汀纸片在螯合MHA(或含100 mg/L EDTA的MHA)上区分暂定野生型与非野生型。
- 该方法遵循CLSI M23开发但未经CLSI审评批准,尚需室间验证和折点确定。
核心结论
- 20-μg利福布汀纸片在螯合MHA或含100 mg/L EDTA的MHA上可清晰、可重复地区分鲍曼不动杆菌暂定野生型与非野生型表型。
- 该方法遵循CLSI M23指南开发,但尚未经CLSI审评或批准,需进一步室间验证和折点确定。
研究设计与样本
- 方法学研究,遵循CLSI M23指南开发利福布汀对鲍曼不动杆菌的纸片扩散药敏方法。
- 在标准MHA和螯合MHA(包括EDTA补充 media)上评估多个纸片含量,将抑菌圈直径与琼脂稀释法MIC进行关联。
- 初步质控测试支持鲍曼不动杆菌NCTC 13304作为候选质控株。
主要发现
- 20-μg RBT纸片在螯合MHA或等效的含100 mg/L EDTA的MHA上提供清晰且可重复的暂定野生型/非野生型区分。
- 常规富铁Mueller-Hinton培养基会系统性低估利福布汀对CRAB的活性。
- 初步质控测试支持A. baumannii NCTC 13304为候选质控株。
关键数值与推荐
- 使用20-μg利福布汀纸片。
- 螯合MHA或MHA补充100 mg/L EDTA。
- 候选质控株为鲍曼不动杆菌NCTC 13304。
临床怎么用
- 在临床微生物实验室中,可采用20-μg利福布汀纸片在螯合MHA(或含100 mg/L EDTA的MHA)上进行鲍曼不动杆菌药敏试验,以更准确评估利福布汀活性。
- 该方法为标准化利福布汀药敏试验、未来折点制定及CRAB更广泛评估提供实用基础。
局限性
- 该研究方法尚未经CLSI审评或批准。
- 尚需室间验证和未来折点确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Carbapenem-resistant Acinetobacter baumannii (CRAB) is an extensively drug-resistant pathogen requiring new therapeutic strategies. Rifabutin (RBT), a U.S. Food and Drug Administration (FDA)-approved rifamycin, has demonstrated potent activity against CRAB; however, its activity is systematically underestimated by conventional antimicrobial susceptibility testing (AST) performed in conventional iron-rich Mueller-Hinton media, necessitating methods that accurately predict in vivo efficacy to guide its clinical use. Here, we describe the development of a disk diffusion method for RBT susceptibility testing against A. baumannii. Following Clinical and Laboratory Standards Institute (CLSI) M23 "Development of In Vitro Susceptibility Test Methods, Breakpoints, and Quality Control Parameters" guidance, multiple disk potencies were evaluated across standard and chelated Mueller-Hinton agar (MHA), including EDTA-supplemented media, and zone-of-inhibition (ZOI) diameters were correlated with MICs determined by agar dilution. A 20-µg RBT disk on chelated MHA, or equivalently on MHA supplemented with 100 mg/L EDTA, provided clear and reproducible discrimination of tentative wild-type and non-wild-type phenotypes, and preliminary quality control testing supported A. baumannii NCTC 13304 as a candidate quality control strain. While this investigational method has not been reviewed or approved by the CLSI, it was developed in concordance with the M23 guidance and addresses the key limitations of conventional AST, providing a robust framework for interlaboratory validation and future breakpoint determination. IMPORTANCE: Antimicrobial susceptibility testing is a critical tool for guiding clinical treatment decisions. Rifabutin exhibits potent activity against carbapenem-resistant Acinetobacter baumannii (CRAB) under the iron-restricted conditions encountered in vivo; however, its activity is systematically underestimated by standard testing methods in iron-rich Mueller-Hinton media. Here, we describe a robust, simple, and reproducible disk diffusion method using a 20-µg rifabutin disk on chelated Mueller-Hinton agar, which enables accurate assessment of rifabutin activity against A. baumannii. Our method provides a practical foundation for standardized rifabutin susceptibility testing, future breakpoint development, and broader evaluation of rifabutin against CRAB to ultimately support its implementation in clinical microbiology laboratories.
引用
- Zorawik M, VanOrman J, Bender L, et al. Rifabutin disk diffusion on chelated Mueller-Hinton agar: a robust methodological framework for accurate Acinetobacter baumannii susceptibility testing. J Clin Microbiol. 2026. PMID: 42813772. doi:10.1128/jcm.00598-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。